BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chang L, Lembo A, Sultan S. American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome. Gastroenterology 2014;147:1149-72.e2. [PMID: 25224525 DOI: 10.1053/j.gastro.2014.09.002] [Cited by in Crossref: 90] [Cited by in F6Publishing: 94] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Barbara G, Cremon C, Bellini M, Corsetti M, Di Nardo G, Falangone F, Fuccio L, Galeazzi F, Iovino P, Sarnelli G, Savarino EV, Stanghellini V, Staiano A, Stasi C, Tosetti C, Turco R, Ubaldi E, Zagari RM, Zenzeri L, Marasco G. Italian guidelines for the management of irritable bowel syndrome: Joint Consensus from the Italian Societies of: Gastroenterology and Endoscopy (SIGE), Neurogastroenterology and Motility (SINGEM), Hospital Gastroenterologists and Endoscopists (AIGO), Digestive Endoscopy (SIED), General Medicine (SIMG), Gastroenterology, Hepatology and Pediatric Nutrition (SIGENP) and Pediatrics (SIP). Dig Liver Dis 2023;55:187-207. [PMID: 36517261 DOI: 10.1016/j.dld.2022.11.015] [Reference Citation Analysis]
2 Chen X, Liu G, Zhao L, Du L, Xie J, Wei D. Lactiplantibacillus plantarum X7022 ameliorates loperamide‐induced constipation and modulates gut microbiota in mice. Food Bioengineering 2022. [DOI: 10.1002/fbe2.12029] [Reference Citation Analysis]
3 Lin Q, Liu M, Erhunmwunsee F, Li B, Mou Y, Wang S, Zhang G, Tian J. Chinese patent medicine shouhui tongbian capsule attenuated loperamide-induced constipation through modulating the gut microbiota in rat. Journal of Ethnopharmacology 2022. [DOI: 10.1016/j.jep.2022.115575] [Reference Citation Analysis]
4 Lembo A, Sultan S, Chang L, Heidelbaugh JJ, Smalley W, Verne GN. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea. Gastroenterology 2022;163:137-51. [PMID: 35738725 DOI: 10.1053/j.gastro.2022.04.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
5 Chang L, Sultan S, Lembo A, Verne GN, Smalley W, Heidelbaugh JJ. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation. Gastroenterology 2022;163:118-36. [PMID: 35738724 DOI: 10.1053/j.gastro.2022.04.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
6 Mourey F, Decherf A, Jeanne JF, Clément-Ziza M, Grisoni ML, Machuron F, Legrain-Raspaud S, Bourreille A, Desreumaux P. Saccharomyces cerevisiae I-3856 in irritable bowel syndrome with predominant constipation. World J Gastroenterol 2022; 28(22): 2509-2522 [DOI: 10.3748/wjg.v28.i22.2509] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 George CM. Chapter 25: Gastrointestinal Diseases. The APhA Complete Review for Pharmacy, 13th Edition 2022. [DOI: 10.21019/9781582123615.ch25] [Reference Citation Analysis]
8 Dan W, Park GH, Vemaraju S, Wu AD, Perez K, Rao M, Berkowitz DE, Lang RA, Yim PD. Light-Mediated Inhibition of Colonic Smooth Muscle Constriction and Colonic Motility via Opsin 3. Front Physiol 2021;12. [DOI: 10.3389/fphys.2021.744294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Layer P, Andresen V, Allescher H, Bischoff SC, Claßen M, Elsenbruch S, Freitag M, Frieling T, Gebhard M, Goebel-Stengel M, Häuser W, Holtmann G, Keller J, Kreis ME, Kruis W, Langhorst J, Jansen PL, Madisch A, Mönnikes H, Müller-Lissner S, Niesler B, Pehl C, Pohl D, Raithel M, Röhrig-Herzog G, Schemann M, Schmiedel S, Schwille-Kiuntke J, Storr M, Preiß JC, Andus T, Buderus S, Ehlert U, Engel M, Enninger A, Fischbach W, Gillessen A, Gschossmann J, Gundling F, Haag S, Helwig U, Hollerbach S, Karaus M, Katschinski M, Krammer H, Kuhlbusch-Zicklam R, Matthes H, Menge D, Miehlke S, Posovszky MC, Schaefert R, Schmidt-Choudhury A, Schwandner O, Schweinlin A, Seidl H, Stengel A, Tesarz J, van der Voort I, Voderholzer W, von Boyen G, von Schönfeld J, Wedel T; Collaborators:., in Zusammenarbeit mit:., Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM)., Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)., Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV)., Deutsche Gesellschaft für Ernährungsmedizin (DGEM)., Deutsche Gesellschaft für Geriatrie (DGG)., Deutsche Gesellschaft für Innere Medizin (DGIM)., Deutsche Gesellschaft für Naturheilkunde (DGNHK)., Deutsche Gesellschaft für Pathologie und Bundesverband deutscher Pathologen e. V. (DGP/BDP)., Deutsche Gesellschaft für Psychosomatische Medizin und Ärztliche Psychotherapie (DGPM)., Deutsche Gesellschaft für Verhaltensmedizin und Verhaltensmodifikation (DGVM)., Deutsche Schmerzgesellschaft e. V., Deutsches Kollegium für Psychosomatische Medizin (DKPM), Deutsche Gesellschaft für Tropenmedizin und Internationale Gesundheit (DTG)., Gesellschaft für Pädiatrische Gastroenterologie und Ernährung (GPGE)., Deutschen Gesellschaft für Kinder- und Jugendmedizin (DGKJ)., Swiss Society of Neurogastroenterology and Motility (SwissNGM)., Informationsforum für Patient:innen mit Magen-Darm-Erkrankungen (MAGDA). Update S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Gemeinsame Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM) – Juni 2021 – AWMF-Registriernummer: 021/016. Z Gastroenterol 2021;59:1323-415. [PMID: 34891206 DOI: 10.1055/a-1591-4794] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Lazebnik LB, Golovanova EV, Volel BA, Korochanskaya NV, Lyalyukova EA, Mokshina MV, Mekhtiev SN, Mekhtieva OA, Metsaeva ZV, Petelin DS, Simanenkov VI, Sitkin SI, Cheremushkin SV, Chernogorova MV, Khavkin АI. Functional gastrointestinal disorders. Overlap syndrome Clinical guidelines of the Russian Scientific Medical Society of Internal Medicine and Gastroenterological Scientific Society of Russia. jour 2021. [DOI: 10.31146/1682-8658-ecg-192-8-5-117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
11 Norwood DA, Dominguez LB, Paredes AA, Montalvan EE, Rodriguez Murillo A, Dougherty MK, Palsson OS, Dominguez RL, Morgan DR. Prevalence and Associated Dietary Factors of Rome IV Functional Gastrointestinal Disorders in Rural Western Honduras. Dig Dis Sci 2021;66:3086-95. [PMID: 33089482 DOI: 10.1007/s10620-020-06639-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Rao SSC, Coss-Adame E, Yan Y, Erdogan A, Valestin J, Ayyala DN. Sensory Adaptation Training or Escitalopram for IBS With Constipation and Rectal Hypersensitivity: A Randomized Controlled Trial. Clin Transl Gastroenterol 2021;12:e00381. [PMID: 34254966 DOI: 10.14309/ctg.0000000000000381] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Liu YW, Wang YP, Yen HF, Liu PY, Tzeng WJ, Tsai CF, Lin HC, Lee FY, Jeng OJ, Lu CL, Tsai YC. Lactobacillus plantarum PS128 Ameliorated Visceral Hypersensitivity in Rats Through the Gut-Brain Axis. Probiotics Antimicrob Proteins 2020;12:980-93. [PMID: 31691208 DOI: 10.1007/s12602-019-09595-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
14 Mahd-Ab Lah N, Kueh YC, Kuan G, Yahaya FH, Wong MS, Abd Samat NA, Hamid N, Mohamad Nor N, Whitehead WE, Thiwan SI, Lee YY. Validity and Reliability of the Malay Versions of Bloating Severity (BSQ-M) and Quality of Life (BLQoL-M) Questionnaires. Int J Environ Res Public Health 2021;18:2487. [PMID: 33802426 DOI: 10.3390/ijerph18052487] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Yaklai K, Pattanakuhar S, Chattipakorn N, Chattipakorn SC. The Role of Acupuncture on the Gut-Brain-Microbiota Axis in Irritable Bowel Syndrome. Am J Chin Med 2021;49:285-314. [PMID: 33622207 DOI: 10.1142/S0192415X21500154] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
16 Kårhus ML, Brønden A, Lyng Forman J, Haaber A, Vilsbøll T, Sonne DP, Knop FKK. Protocol for a randomised, double-blinded, placebo-controlled, double-dummy 6-week clinical trial comparing the treatment effects of the glucagon-like peptide 1 receptor agonist liraglutide versus the bile acid sequestrant colesevelam on bile acid malabsorption. BMJ Open 2021;11:e044711. [PMID: 33558360 DOI: 10.1136/bmjopen-2020-044711] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Gonzalez Alonso R, Gomez MF, O’dowd MA. Psychiatric Issues in Older Adults with Gastrointestinal Disorders. Geriatric Gastroenterology 2021. [DOI: 10.1007/978-3-030-30192-7_92] [Reference Citation Analysis]
18 Zhang Q, Zhong D, Sun R, Zhang Y, Pegg RB, Zhong G. Prevention of loperamide induced constipation in mice by KGM and the mechanisms of different gastrointestinal tract microbiota regulation. Carbohydr Polym 2021;256:117418. [PMID: 33483010 DOI: 10.1016/j.carbpol.2020.117418] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
19 Sebastián Domingo J, Sánchez Sánchez C. La dieta baja en FODMAP, ¿es realmente eficaz y segura en el síndrome del intestino irritable?: una revisión panorámica. Medicina de Familia SEMERGEN 2020;46:566-76. [DOI: 10.1016/j.semerg.2020.07.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
20 Zhang Y, Zhang L, Li S, Wu XX, Bi YX, Hu X, Chen YQ, Yuan Y. Serum levels of high sensitive C-reactive protein and tumor necrosis factor-alpha in different subtypes of irritable bowel syndrome and their correlation. Shijie Huaren Xiaohua Zazhi 2020; 28(16): 782-788 [DOI: 10.11569/wcjd.v28.i16.782] [Reference Citation Analysis]
21 Roenneberg C, Sattel H, Schaefert R, Henningsen P, Hausteiner-Wiehle C. Functional Somatic Symptoms. Dtsch Arztebl Int 2019;116:553-60. [PMID: 31554544 DOI: 10.3238/arztebl.2019.0553] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
22 Shakya AK, Naik RR, Almasri IM, Kaur A. Role and Function of Adenosine and its Receptors in Inflammation, Neuroinflammation, IBS, Autoimmune Inflammatory Disorders, Rheumatoid Arthritis and Psoriasis. Curr Pharm Des 2019;25:2875-91. [PMID: 31333103 DOI: 10.2174/1381612825666190716145206] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
23 Chandrasekaran B, Samarneh S, Jaber AMY, Kassab G, Agrawal N. Therapeutic Potentials of A2B Adenosine Receptor Ligands: Current Status and Perspectives. Curr Pharm Des 2019;25:2741-71. [PMID: 31333084 DOI: 10.2174/1381612825666190717105834] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
24 Liu R, Staller K. Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives. Drug Des Devel Ther 2020;14:1391-400. [PMID: 32308371 DOI: 10.2147/DDDT.S216056] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
25 Farmer AD, Aziz Q. Irritable bowel syndrome. Oxford Textbook of Medicine 2020. [DOI: 10.1093/med/9780198746690.003.0308] [Reference Citation Analysis]
26 Chen FW, LeBrett WG, Yang L, Chang L. Opioid Prescription Patterns Among US Gastroenterologists From 2013 to 2017. Gastroenterology 2020;158:776-779.e2. [PMID: 31647903 DOI: 10.1053/j.gastro.2019.10.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
27 Zhang Y, Wu XX, Li S, Wu JF, Han S, Lin ZJ, Ding SZ, Gong WJ. Peroxiredoxin 1 as an inflammatory marker in diarrhea-predominant and postinfectious irritable bowel syndrome. Neurogastroenterol Motil 2020;32:e13741. [PMID: 31613423 DOI: 10.1111/nmo.13741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
28 Sarkar S, Choudhury S, Balasundaram S, Balasubramanian SP. Depression and anxiety associated with functional bowel disorders and its impact on quality of life: A cross-sectional study. Ind Psychiatry J 2020;29:68-75. [PMID: 33776278 DOI: 10.4103/ipj.ipj_59_18] [Reference Citation Analysis]
29 Gonzalez Alonso R, Gomez MF, O’dowd MA. Psychiatric Issues in Older Adults with Gastrointestinal Disorders. Geriatric Gastroenterology 2020. [DOI: 10.1007/978-3-319-90761-1_92-1] [Reference Citation Analysis]
30 Dai L, Zhong LL, Ji G. Irritable bowel syndrome and functional constipation management with integrative medicine: A systematic review. WJCC 2019;7:3469-87. [DOI: 10.12998/wjcc.v7.i21.3469] [Reference Citation Analysis]
31 Dai L, Zhong LL, Ji G. Irritable bowel syndrome and functional constipation management with integrative medicine: A systematic review. World J Clin Cases 2019; 7(21): 3486-3504 [PMID: 31750331 DOI: 10.12998/wjcc.v7.i21.3486] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
32 Hadjivasilis A, Tsioutis C, Michalinos A, Ntourakis D, Christodoulou DK, Agouridis AP. New insights into irritable bowel syndrome: from pathophysiology to treatment. Ann Gastroenterol 2019;32:554-64. [PMID: 31700231 DOI: 10.20524/aog.2019.0428] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
33 Brenner DM, Sayuk GS, Gutman CR, Jo E, Elmes SJR, Liu LWC, Cash BD. Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study. Am J Gastroenterol 2019;114:1502-11. [PMID: 31356229 DOI: 10.14309/ajg.0000000000000327] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 8.3] [Reference Citation Analysis]
34 Camilleri M. Management Options for Irritable Bowel Syndrome. Mayo Clin Proc. 2018;93:1858-1872. [PMID: 30522596 DOI: 10.1016/j.mayocp.2018.04.032] [Cited by in Crossref: 48] [Cited by in F6Publishing: 35] [Article Influence: 12.0] [Reference Citation Analysis]
35 Love BL. Plecanatide for Treatment of Chronic Constipation and Irritable Bowel Syndrome. Am J Med 2019;132:572-5. [PMID: 30550753 DOI: 10.1016/j.amjmed.2018.11.027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
36 Basnayake C, Kamm MA, Salzberg M, Stanley A, Khera A, Burrell K, Wilson-o’brien A, Hebbard G, Thompson AJ. Outcome of hospital outpatient treatment of functional gastrointestinal disorders: Functional gastrointestinal disorders. Intern Med J 2019;49:225-31. [DOI: 10.1111/imj.14067] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
37 Colombel JF, Shin A, Gibson PR. AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review. Clin Gastroenterol Hepatol 2019;17:380-390.e1. [PMID: 30099108 DOI: 10.1016/j.cgh.2018.08.001] [Cited by in Crossref: 70] [Cited by in F6Publishing: 54] [Article Influence: 17.5] [Reference Citation Analysis]
38 Moayyedi P, Andrews CN, MacQueen G, Korownyk C, Marsiglio M, Graff L, Kvern B, Lazarescu A, Liu L, Paterson WG, Sidani S, Vanner S. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). J Can Assoc Gastroenterol 2019;2:6-29. [PMID: 31294724 DOI: 10.1093/jcag/gwy071] [Cited by in Crossref: 57] [Cited by in F6Publishing: 66] [Article Influence: 14.3] [Reference Citation Analysis]
39 Ford AC, Lacy BE, Harris LA, Quigley EMM, Moayyedi P. Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. Am J Gastroenterol 2019;114:21-39. [PMID: 30177784 DOI: 10.1038/s41395-018-0222-5] [Cited by in Crossref: 173] [Cited by in F6Publishing: 215] [Article Influence: 43.3] [Reference Citation Analysis]
40 Kim JH, Jee SR. Irritable Bowel Syndrome. Korean J Gastroenterol 2019;73:84. [DOI: 10.4166/kjg.2019.73.2.84] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
41 Connell M, Shin A, James-Stevenson T, Xu H, Imperiale TF, Herron J. Systematic review and meta-analysis: Efficacy of patented probiotic, VSL#3, in irritable bowel syndrome. Neurogastroenterol Motil 2018;30:e13427. [PMID: 30069978 DOI: 10.1111/nmo.13427] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
42 Olden KW, Chey WD, Shringarpure R, Paul Nicandro J, Chuang E, Earnest DL. Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome. Current Medical Research and Opinion 2019;35:461-72. [DOI: 10.1080/03007995.2018.1533456] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
43 Albusoda A, Ruffle JK, Friis KA, Gysan MR, Drewes AM, Aziz Q, Farmer AD. Systematic review with meta-analysis: conditioned pain modulation in patients with the irritable bowel syndrome. Aliment Pharmacol Ther 2018;48:797-806. [PMID: 30206948 DOI: 10.1111/apt.14965] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
44 Islam BN, Sharman SK, Browning DD. Clinical utility of plecanatide in the treatment of chronic idiopathic constipation. Int J Gen Med 2018;11:323-30. [PMID: 30127634 DOI: 10.2147/IJGM.S125051] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
45 Ramírez FB, Mas MT, Núñez CG, Jiménez NR, Vargas MR. La alimentación en el síndromedel intestino irritabletie. FMC - Formación Médica Continuada en Atención Primaria 2018;25:422-432. [DOI: 10.1016/j.fmc.2017.07.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
46 Jia M, Lu X, Wang Z, Zhao L, Zhang S. Effects of Fengliao-Changweikang in Diarrhea-predominant Irritable Bowel Syndrome Rats and Its Mechanism Involving Colonic Motility. J Neurogastroenterol Motil 2018;24:479-89. [PMID: 29715711 DOI: 10.5056/jnm17093] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
47 Wiley JW, Chang L. Functional Bowel Disorders. Gastroenterology 2018;155:1-4. [PMID: 29454798 DOI: 10.1053/j.gastro.2018.02.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
48 Yang Y, Fang J, Guo X, Dai N, Shen X, Yang Y, Sun J, Bhandari BR, Reasner DS, Cronin JA, Currie MG, Johnston JM, Zeng P, Montreewasuwat N, Chen GZ, Lim S. Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions. J Gastroenterol Hepatol 2018;33:980-9. [PMID: 29319191 DOI: 10.1111/jgh.14086] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
49 Song KH, Jung HK, Kim HJ, Koo HS, Kwon YH, Shin HD, Lim HC, Shin JE, Kim SE, Cho DH, Kim JH, Kim HJ; Clinical Practice Guidelines Group Under the Korean Society of Neurogastroenterology and Motility. Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition. J Neurogastroenterol Motil. 2018;24:197-215. [PMID: 29605976 DOI: 10.5056/jnm17145] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
50 Cong X, Ramesh D, Perry M, Xu W, Bernier KM, Young EE, Walsh S, Starkweather A. Pain self-management plus nurse-led support in young adults with irritable bowel syndrome: Study protocol for a pilot randomized control trial. Res Nurs Health 2018;41:121-30. [PMID: 29388674 DOI: 10.1002/nur.21862] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
51 Radovanovic-Dinic B, Tesic-Rajkovic S, Grgov S, Petrovic G, Zivkovic V. Irritable bowel syndrome - from etiopathogenesis to therapy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2018;162:1-9. [PMID: 29358788 DOI: 10.5507/bp.2017.057] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
52 Whelan K, Martin LD, Staudacher HM, Lomer MCE. The low FODMAP diet in the management of irritable bowel syndrome: an evidence-based review of FODMAP restriction, reintroduction and personalisation in clinical practice. J Hum Nutr Diet 2018;31:239-55. [DOI: 10.1111/jhn.12530] [Cited by in Crossref: 146] [Cited by in F6Publishing: 152] [Article Influence: 29.2] [Reference Citation Analysis]
53 Jung H. Review of the Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition. Korean J Gastroenterol 2018;72:252. [DOI: 10.4166/kjg.2018.72.5.252] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
54 Asano T, Takenaga M. Adenosine A2B Receptors: An Optional Target for the Management of Irritable Bowel Syndrome with Diarrhea? J Clin Med 2017;6:E104. [PMID: 29099770 DOI: 10.3390/jcm6110104] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
55 George CM. Chapter 25: Gastrointestinal Diseases. The APhA Complete Review for Pharmacy, 12th edition 2017. [DOI: 10.21019/9781582122816.ch25] [Reference Citation Analysis]
56 Camilleri M, Ford AC. Pharmacotherapy for Irritable Bowel Syndrome. J Clin Med 2017;6:E101. [PMID: 29077050 DOI: 10.3390/jcm6110101] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
57 Sharma A, Rao S. Constipation: Pathophysiology and Current Therapeutic Approaches. Handb Exp Pharmacol. 2017;239:59-74. [PMID: 28185025 DOI: 10.1007/164_2016_111] [Cited by in Crossref: 56] [Cited by in F6Publishing: 33] [Article Influence: 9.3] [Reference Citation Analysis]
58 Camilleri M, Ford AC. Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches.Handb Exp Pharmacol. 2017;239:75-113. [PMID: 27995391 DOI: 10.1007/164_2016_102] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
59 Coates MD, Tekin I, Vrana KE, Mawe GM. Review article: the many potential roles of intestinal serotonin (5-hydroxytryptamine, 5-HT) signalling in inflammatory bowel disease. Aliment Pharmacol Ther 2017;46:569-80. [PMID: 28737264 DOI: 10.1111/apt.14226] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 8.2] [Reference Citation Analysis]
60 Cong X, Perry M, Bernier KM, Young EE, Starkweather A. Effects of Self-Management Interventions in Patients With Irritable Bowel Syndrome: Systematic Review. West J Nurs Res 2018;40:1698-720. [PMID: 28854852 DOI: 10.1177/0193945917727705] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
61 Asano T, Tanaka KI, Tada A, Shimamura H, Tanaka R, Maruoka H, Mizushima T, Takenaga M. Ameliorative effect of chlorpromazine hydrochloride on visceral hypersensitivity in rats: possible involvement of 5-HT2A receptor.Br J Pharmacol. 2017;174:3370-3381. [PMID: 28750135 DOI: 10.1111/bph.13960] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
62 Staudacher HM, Whelan K. The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS. Gut 2017;66:1517-27. [PMID: 28592442 DOI: 10.1136/gutjnl-2017-313750] [Cited by in Crossref: 198] [Cited by in F6Publishing: 173] [Article Influence: 33.0] [Reference Citation Analysis]
63 Levio S, Cash BD. The place of eluxadoline in the management of irritable bowel syndrome with diarrhea. Therap Adv Gastroenterol 2017;10:715-25. [PMID: 28932272 DOI: 10.1177/1756283X17721152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
64 Sayuk GS, Wolf R, Chang L. Comparison of Symptoms, Healthcare Utilization, and Treatment in Diagnosed and Undiagnosed Individuals With Diarrhea-Predominant Irritable Bowel Syndrome. Am J Gastroenterol 2017;112:892-9. [PMID: 28094313 DOI: 10.1038/ajg.2016.574] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
65 Lacy BE, Chey WD, Cash BD, Lembo AJ, Dove LS, Covington PS. Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use. Am J Gastroenterol 2017;112:924-32. [PMID: 28417992 DOI: 10.1038/ajg.2017.72] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
66 Lin WT, Liao YJ, Peng YC, Chang CH, Lin CH, Yeh HZ, Chang CS. Relationship between use of selective serotonin reuptake inhibitors and irritable bowel syndrome: A population-based cohort study. World J Gastroenterol 2017; 23(19): 3513-3521 [PMID: 28596687 DOI: 10.3748/wjg.v23.i19.3513] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
67 Sebastián Domingo JJ. The new Rome criteria (IV) of functional digestive disorders in clinical practice. Medicina Clínica (English Edition) 2017;148:464-468. [DOI: 10.1016/j.medcle.2016.12.070] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
68 Wilhelm S, Mcconachie S, Kale-pradhan P. Diarrhea, Constipation, and Irritable Bowel Syndrome. PharmacotherapyFirst: A Multimedia Learning Resource 2017. [DOI: 10.21019/pharmacotherapyfirst.ibs_overview] [Reference Citation Analysis]
69 Sebastián Domingo JJ. The new Rome criteria (IV) of functional digestive disorders in clinical practice. Med Clin (Barc) 2017;148:464-8. [PMID: 28153434 DOI: 10.1016/j.medcli.2016.12.020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
70 Shah SL, Lacy BE. Dietary Interventions and Irritable Bowel Syndrome: A Review of the Evidence. Curr Gastroenterol Rep. 2016;18:41. [PMID: 27372289 DOI: 10.1007/s11894-016-0517-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
71 Cayzeele-Decherf A, Pélerin F, Leuillet S, Douillard B, Housez B, Cazaubiel M, Jacobson GK, Jüsten P, Desreumaux P. Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis. World J Gastroenterol 2017; 23(2): 336-344 [PMID: 28127207 DOI: 10.3748/wjg.v23.i2.336] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
72 Simrén M, Törnblom H, Palsson OS, Whitehead WE. Management of the multiple symptoms of irritable bowel syndrome. Lancet Gastroenterol Hepatol 2017;2:112-22. [PMID: 28403981 DOI: 10.1016/S2468-1253(16)30116-9] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 7.2] [Reference Citation Analysis]
73 Asano T, Tanaka KI, Tada A, Shimamura H, Tanaka R, Maruoka H, Takenaga M, Mizushima T. Aminophylline suppresses stress-induced visceral hypersensitivity and defecation in irritable bowel syndrome. Sci Rep 2017;7:40214. [PMID: 28054654 DOI: 10.1038/srep40214] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
74 Buono JL, Mathur K, Averitt AJ, Andrae DA. Economic burden of inadequate symptom control among US commercially insured patients with irritable bowel syndrome with diarrhea. J Med Econ 2017;20:353-62. [PMID: 27919177 DOI: 10.1080/13696998.2016.1269016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
75 Lucak S, Chang L, Halpert A, Harris LA. Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice. Therap Adv Gastroenterol 2017;10:253-75. [PMID: 28203283 DOI: 10.1177/1756283X16663396] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
76 Sanger GJ. Chronic constipation: improved understanding offers a new therapeutic approach. J Physiol 2016;594:4085-7. [PMID: 27477601 DOI: 10.1113/JP272560] [Reference Citation Analysis]
77 Rao SS, Rattanakovit K, Patcharatrakul T. Diagnosis and management of chronic constipation in adults. Nat Rev Gastroenterol Hepatol 2016;13:295-305. [PMID: 27033126 DOI: 10.1038/nrgastro.2016.53] [Cited by in Crossref: 154] [Cited by in F6Publishing: 146] [Article Influence: 22.0] [Reference Citation Analysis]
78 Foxx-Orenstein AE. New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists. Therap Adv Gastroenterol 2016;9:354-75. [PMID: 27134665 DOI: 10.1177/1756283X16633050] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
79 Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. Bowel Disorders. Gastroenterology 2016:S0016-5085(16)00222-5. [PMID: 27144627 DOI: 10.1053/j.gastro.2016.02.031] [Cited by in Crossref: 1466] [Cited by in F6Publishing: 1470] [Article Influence: 209.4] [Reference Citation Analysis]
80 Camilleri M, Bueno L, Andresen V, De Ponti F, Choi MG, Lembo A. Pharmacological, Pharmacokinetic, and Pharmacogenomic Aspects of Functional Gastrointestinal Disorders. Gastroenterology 2016:S0016-5085(16)00220-1. [PMID: 27144621 DOI: 10.1053/j.gastro.2016.02.029] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
81 Thomas LV, Suzuki K, Zhao J. Probiotics: a proactive approach to health. A symposium report. Br J Nutr 2015;114 Suppl 1:S1-15. [PMID: 26548336 DOI: 10.1017/S0007114515004043] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.7] [Reference Citation Analysis]
82 Makharia A, Catassi C, Makharia GK. The Overlap between Irritable Bowel Syndrome and Non-Celiac Gluten Sensitivity: A Clinical Dilemma. Nutrients 2015;7:10417-26. [PMID: 26690475 DOI: 10.3390/nu7125541] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 7.0] [Reference Citation Analysis]
83 Philpott H, Nandurkar S, Lubel J, Gibson PR. Food, fibre, bile acids and the pelvic floor: An integrated low risk low cost approach to managing irritable bowel syndrome. World J Gastroenterol 2015; 21(40): 11379-11386 [PMID: 26525925 DOI: 10.3748/wjg.v21.i40.11379] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
84 Cassell B, Gyawali CP, Kushnir VM, Gott BM, Nix BD, Sayuk GS. Beliefs about GI medications and adherence to pharmacotherapy in functional GI disorder outpatients. Am J Gastroenterol 2015;110:1382-7. [PMID: 25916226 DOI: 10.1038/ajg.2015.132] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
85 Mayer EA, Labus JS, Tillisch K, Cole SW, Baldi P. Towards a systems view of IBS. Nat Rev Gastroenterol Hepatol 2015;12:592-605. [PMID: 26303675 DOI: 10.1038/nrgastro.2015.121] [Cited by in Crossref: 165] [Cited by in F6Publishing: 148] [Article Influence: 20.6] [Reference Citation Analysis]
86 Shi Y, Chen YH, Yin XJ, Wang AQ, Chen XK, Lu JH, Ji R, Bao CH, Sun J, Zhao JM, Wu HG. Electroacupuncture versus Moxibustion for Irritable Bowel Syndrome: A Randomized, Parallel-Controlled Trial. Evid Based Complement Alternat Med 2015;2015:361786. [PMID: 26294923 DOI: 10.1155/2015/361786] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
87 Lacy BE, Schey R, Shiff SJ, Lavins BJ, Fox SM, Jia XD, Blakesley RE, Hao X, Cronin JA, Currie MG, Kurtz CB, Johnston JM, Lembo AJ. Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial. PLoS One 2015;10:e0134349. [PMID: 26222318 DOI: 10.1371/journal.pone.0134349] [Cited by in Crossref: 45] [Cited by in F6Publishing: 51] [Article Influence: 5.6] [Reference Citation Analysis]
88 Slattery SA, Niaz O, Aziz Q, Ford AC, Farmer AD. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther 2015;42:3-11. [PMID: 25913530 DOI: 10.1111/apt.13227] [Cited by in Crossref: 118] [Cited by in F6Publishing: 101] [Article Influence: 14.8] [Reference Citation Analysis]
89 News. Gastrointestinal Nursing 2014;12:6-7. [DOI: 10.12968/gasn.2014.12.10.6] [Reference Citation Analysis]
90 Weinberg DS, Smalley W, Heidelbaugh JJ, Sultan S; Amercian Gastroenterological Association. American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome. Gastroenterology 2014;147:1146-8. [PMID: 25224526 DOI: 10.1053/j.gastro.2014.09.001] [Cited by in Crossref: 75] [Cited by in F6Publishing: 79] [Article Influence: 8.3] [Reference Citation Analysis]